Overview
ACTU market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ACTU price chart · 1M
- O
- 0.290000
- H
- 0.290000
- L
- 0.290000
- C
- 0.290000
- Vol
- 134.00
Daily history from Aug 13, 2024
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $0.29
- Previous Close
- $0.25
- Day High
- $0.29
- Day Low
- $0.29
- 52 Week High
- $7.80
- 52 Week Low
- $0.24
- 7 Day Return
- -5.17%
- 30 Day Return
- -51.01%
- 90 Day Return
- -76.42%
- 1 Year Return
- -95.13%
- Daily Notional Volume
- $38.9 Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.61 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.28 – $7.90 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $14.7M · P/B 17.95.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
HC Wainwright Adjusts Price Target on Actuate Therapeutics to $10 From $15, Keeps Buy RatingFiscal.ai ·
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral TabletsFiscal.ai ·